Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Actrapid® (Insulin), soluble human insulin
Actrapid · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| 10% Hemohes® (10% Hydroxyethyl starch) | DRUG | - |
| Sterofundin® (Ringer lactate solution) | DRUG | - |
| Actrapid® (Insulin) | DRUG | - |
Inclusion Criteria: * Patients fulfilling the criteria of "severe sepsis" or "septic shock" according to the Society of Critical Care Medicine/American College of Chest Physicians (SCCM/ACCP) definitions not longer than 24 hours before ICU admission or 12 hours after ICU admission Exclusion Criter...
Actrapid is being studied as an insulin therapy in severe sepsis and septic shock. It was evaluated in the Phase 3 VISEP trial, which examined intensive insulin therapy alongside volume substitution in critically ill adults with severe sepsis. Actrapid is not approved for severe sepsis and remains investigational for this indication.
Actrapid is developed and manufactured by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the Phase 3 VISEP trial that evaluated Actrapid in severe sepsis.
Actrapid is in Phase 3 development for severe sepsis. The VISEP trial, registered as NCT00135473, was a Phase 3 study that has been completed. Actrapid is investigational for severe sepsis and is not approved for that indication.
Actrapid was evaluated in the VISEP trial, NCT00135473, titled Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis. The Phase 3 trial enrolled 600 adults aged 18 years and older in Germany and has been completed. It was randomized but not double blinded, with an uncontrolled design.
Yes. Actrapid and Actrapid (Insulin) refer to the same product from Novo Nordisk A/S. Actrapid is an insulin therapy, and the alternative name Actrapid (Insulin) is used interchangeably in reference to the same drug.